User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

All Publications

Displaying 8 results.
    • Journal article
    DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment
    Cruyssen, BV Van Looy, S. Wyns, B Westhovens, Rene[UCL] Durez, Patrick[UCL] Van den Bosch, F. Veys, Éric M. Mielants, H. DE Clerck, L. Peretz, A. Malaise, Michel Verbruggen, L. Vastesaeger, N. Geldhof, A. Boullart, L. De Keyser, F. (2005) Arthritis Research & Therapy — Vol. 7, no. 5, p. R1063-R1071 (2005)
    • Speech
    Four year follow-up of infliximab in rheumatoid arthritis patients refractory to multiple dmard treatment: Attrition and long-term clinical effect
    Cruyssen, B. Vander Durez, Patrick[UCL] Westhovens, Rene[UCL] Van den Bosch, F. Mielants, H. De Clerck, L. Peretz, A. Malaise, Michel Verbruggen, L. Vastesaegere, N. Geldhof, A. De Keyser, F. (2006) Annual European Congress of Rheumatology (EULAR 2006) — Amsterdam (Netherlands)
    • Journal article
    Timing of DAS28 in infliximab therapy: reply
    Durez, Patrick[UCL] Van den Bosch, F. Corluy, L Veys, Emilie[UCL] De Clerck, L. Peretz, A. Malaise, Michel Devogelaer, Jean-Pierre[UCL] Vastesaeger, N. Geldhof, A. Westhovens, Rene[UCL] (2005) Rheumatology — Vol. 44, no. 9, p. 1204-1204 (2005)
    • Speech
    Long-term safety of infliximab (INX) with methotrexate (MTX) in a large belgian observational patient cohort with severe, refractory rheumatoid arthritis (RA)
    Durez, Patrick[UCL] Devogelaer, Jean-Pierre[UCL] Vander Cruyssen, B. Vandenbosch, F. Vastesaeger, N. Geldhof, A. De Keyser, F. Verbruggen, L. De Clerck, L. Peretz, A. Malaise, Michel Van Heuverbeke, F. Westhovens, Rene[UCL] (2006) Annual European Congress of Rheumatology (EULAR 2006) — Amsterdam (Netherlands)
    • Speech
    Evaluation of the DAS28 at week 14 or week 22 correlates best with long term attrition to infliximab therapy in rheumatoid arthritis patients
    Cruyssen, B. Vander Durez, Patrick[UCL] Van Looy, S. Wijns, B. Westhovens, Rene[UCL] Van den Bosch, F. Mielants, H. De Clerck, L. Peretz, A. Malaise, Michel Verbruggen, L. Vastesaeger, N. Geldhof, A. Boullart, L. De Keyser, F. (2006) Annual European Congress of Rheumatology (EULAR 2006) — Amsterdam (Netherlands)
    • Speech
    Tapering infliximab dosages after temporary dose increase does not affect treatment survival in an established RA population
    Vander Cruyssen, B. Durez, Patrick[UCL] Westhovens, Rene[UCL] Van den Bosch, F. Mielants, H. De Clerck, L. Peretz, A. Malaise, Michel Verbruggen, L. Dewulf, L. Vastesaeger, N. Geldhof, A. Noel, W. Boullart, L.[UCL] De Keyser, F. (2008) —
    • Speech
    Das28 correlates best with the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients
    Vander Cruyssen, B. Durez, Patrick[UCL] Devogelaer, Jean-Pierre[UCL] Van Looy, S. Westhovens, Rene[UCL] Van den Bosch, F. Veys, Emilie[UCL] De Clerck, L. Peretz, A. Malaise, Michel Verbruggen, L. Vastesaeger, N. Geldhof, A. Boulart, L De Keyser, F. (2005) Annual European Congress of Rheumatology — Vienna (Austria)
    • Journal article
    A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study
    Durez, Patrick[UCL] Van den Bosch, F. Corluy, L Veys, Emilie[UCL] De Clerck, L. Peretz, A. Malaise, Michel Devogelaer, Jean-Pierre[UCL] Vastesaeger, N. Geldhof, A. Westhovens, Rene[UCL] (2005) Rheumatology — Vol. 44, no. 4, p. 465-468 (2005)